Julian's Polymath Explorations

"You are incredibly prescient!"   I woke up to those words from a former colleague on Jan. 19, 2022: the bombshell announcement that the Chief Science Officer of pharma giant GSK, where I worked until recently, will become the CEO at the new, $3 BILLION longevity science company Altos (presumably also funded by Amazon's Jeff Bezos.) Big Pharma is at long last embracing Longevity Science. The corollary: longevity science is entering Mainstream (with capital "M") But let me backtrack... The Decade of Longevity Science When Harvard professor David Sinclair declared the 2020's to be the " decade of the paradigm shift about age reversal ", one could perhaps be dismissive of it as just an outburst of enthusiasm... But in the past couple of years, we're seeing strong evidence that his forecast is right on the mark! While I worked at GlaxoSmithKline - a giant, top-10, pharma company - I vigorously advocated forming a Longevity Science dept., and sp...

Ending Age-Related Diseases 2021 The conference just ended on Aug. 22.  Here's one of the talks... Link to conference  (Notes and screenshots taken - and sometimes annotated - by me.) Science at SENS Research Foundation 2021 Talk by Alexandra Stolzing , Professor for Biogerontological Engineering, VP of Research at SENS Research Foundation ("Strategies for Engineered Negligible Senescence".) This overview talk immediately emphasizes that the aging process involves multiple broad fundamental categories of physiological change.  Those are related to what are often referred as "the Hallmarks of Aging" , as I detail in my intro post on Longevity Science .  In this talk, 7 of those categories are identified, and given convenient icons (rightmost column) that make it easier to refer to them: The SENS foundation has both intramural and extramural projects happening, and tries to have at least one project in each of the above broad categories.  (But currently no projec...